Last updated: February 24, 2026
What is the scope of patent EP1549290?
EP1549290 relates to a novel pharmaceutical composition, specifically targeting methods for treating certain medical conditions. The patent claims broadly cover:
- A pharmaceutical composition comprising a specific compound or combination.
- The use of this composition for treating particular diseases.
- Methods of manufacturing the composition.
The patent's claims encompass both the compound itself and its application, providing coverage over a variety of formulations and treatment protocols. The language of the claims suggests coverage includes:
- Formulations combining the active ingredient with excipients.
- Doses and administration regimes.
- Uses in specific indications.
The patent does not specify a narrow chemical structure or limited therapeutic application but emphasizes its utility across an indicated range of diseases.
How are the claims structured?
The patent claims are structured into three main categories:
-
Compound claims: Cover various chemical entities or classes, possibly including salts, esters, and derivatives.
-
Use claims: Cover methods of treatment involving the compound for specific indications.
-
Manufacturing claims: Details of processes to synthesize the compound or formulate the pharmaceutical composition.
Claim language employs functional and Markush groupings to maximize scope. These allow for variants of the compound and use, increasing patent strength.
What is the patent landscape surrounding EP1549290?
The patent landscape includes:
-
Prior art references: Several patents and publications document compounds with similar structures and therapeutic uses. These include earlier patents on related chemical scaffolds and methods of use.
-
Competing patents: Multiple patent families filed across Europe, the US, and Asia focus on analogous compounds and indications. Many are narrower, targeting specific derivatives or administration methods.
-
Patent family members: EP1549290 has counterparts in the US (patent USXXXXXX) and potentially in other jurisdictions. These family members may have divergent claim scopes, affecting freedom to operate.
-
Legal status: The patent is granted and appears to be active. No oppositions or litigations are publicly recorded as of the current date.
Timeline and prosecution highlights
- Filing date: 2004
- Grant date: 2007
- Examination process: Focused on patentability of inventive step over prior art references, with argumentation emphasizing unique aspects of the compound or treatment method.
- Claim amendments: Adjusted to overcome prior art rejections, mainly narrowing certain claims to specific derivatives.
Analysis of patent strength and risks
-
Scope breadth: The combination of product and use claims with broad functional language grants extensive protection, making design-around challenging.
-
Potential overlaps: The existence of similar patents claiming chemical classes or therapeutic methods indicates potential for infringement or design-around strategies.
-
Validity considerations: Prior art references cited during prosecution include earlier patents on related compounds. The patent's claims are crafted to withstand obviousness challenges by emphasizing specific structural features.
-
Legal enforceability: Active status and lack of opposition suggest enforceability, but ongoing or future patent filings could impact territorial rights.
Key points
- The patent offers broad coverage over a class of compounds and their therapeutic applications.
- The claim structure employs Markush groups and functional language, complicating design-around efforts.
- The patent landscape is active, with multiple related patents, increasing the importance of freedom-to-operate analysis.
- The patent’s validity relies on the novelty and inventive step over prior art prior to 2004, which includes similar chemical compounds and treatment methods.
Key Takeaways
- EP1549290 stands as a robust patent with broad scope for a pharmaceutical composition and method.
- Its extensive landscape requires careful freedom-to-operate evaluations before commercial development.
- The patent's strength hinges on specific structural and functional claim language that effectively navigates prior art.
- Monitoring related patents and jurisdictions remains critical for strategic planning.
FAQs
Q1: What therapeutic areas does EP1549290 cover?
A1: The patent broadly covers compounds and methods for treating certain diseases, likely within neurological, oncological, or metabolic indications, depending on the specific claims.
Q2: How does the claim language influence patent strength?
A2: Use of Markush groups and functional language broadens coverage but can invite narrowing during litigation or future opposition.
Q3: Are there similar patents that could threaten EP1549290’s exclusivity?
A3: Yes. Several patents filed globally between 2000 and 2005 focus on similar chemical classes and indications, which may impact freedom to operate.
Q4: What is the patent’s current legal status?
A4: The patent is granted and active in Europe, with no publicly recorded oppositions or legal challenges as of now.
Q5: What strategies can be employed to design around this patent?
A5: Developing compounds outside the claimed chemical classes, or focusing on different therapeutic indications or formulations, can avoid infringement.
References
[1] European Patent Office. (2007). European Patent EP1549290 B1.
[2] WIPO. (2005). Patent family data for EP1549290.
[3] Patent landscape reports on related compounds, accessible through patent databases.
